Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings, Inc. - Common Stock (NQ: BPTH )

0.2100 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.2100
Bid (Size) 0.2001 (50)
Ask (Size) 0.2142 (42)
Prev. Close 0.2100
Today's Range 0.2100 - 0.2100
52wk Range 0.2100 - 7.670
Shares Outstanding 4,306,892
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Which stocks are moving on Tuesday?
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill

Performance

YTD
-81.74%
-81.74%
1 Month
-71.47%
-71.47%
3 Month
-70.63%
-70.63%
6 Month
-78.35%
-78.35%
1 Year
-96.26%
-96.26%

More News

Read More
Tuesday's session: gap up and gap down stocks
Via Chartmill
Uncovering Potential: Bio-Path Holdings's Earnings Preview
Via Benzinga
US Stocks Mixed; NY State Business Activity Rises In February
Via Benzinga
Wondering what's happening in today's pre-market session?
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Expands Global Patent Portfolio
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides Key Clinical Updates
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session?
Via Chartmill
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides 2025 Clinical and Operational Update
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline
Via Benzinga
Bio-Path Holdings Shares Were On The Rise: What's Going On?
Via Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge
Via Benzinga
US Stocks Higher, Micron Reports Downbeat Sales
Via Benzinga
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
Via Newsfile
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Earnings Scheduled For November 15, 2024
Via Benzinga
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.